DDW’s Megan Thomas caught up with Philipp Baaske, Co-Founder & Executive Chairman of NanoTemper Technologies, about biophysical characterisation techniques for complex biologics. Read More
In one of his first acts as President, Donald Trump signed an executive order to withdraw the US from the World Health Organization (WHO). DDW’s Megan Thomas spoke with three industry leaders to understand the impact this will have on the drug development sector. Cell and gene therapy According to… Read More
Acacia Parks, PhD, MBA, Advisor to Lindus Health, discusses the journey to commercialisation for digital therapeutics and how best to engage the FDA in this process. While there is no “one size fits all” approach to the development of any class of treatments, this is especially true for digital therapeutics… Read More
In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More
Webinar date: Supported by Amazon Web Services and NVIDIA #News
#AI / data analytics / healthtech / informatics#Amazon Web Services (AWS)#Artificial intelligence (AI)#Drug development#Drug discovery#Generative AI
In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More
Webinar date: Supported by Amazon Web Services and NVIDIA #News
#AI / data analytics / healthtech / informatics#Amazon Web Services (AWS)#Artificial intelligence (AI)#Drug development#Drug discovery#Generative AI
In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More
Webinar date: Supported by Amazon Web Services and NVIDIA #News
The Winter issue of Drug Discovery World (DDW) is out now and asks why sex and gender need to be recognised in drug discovery. Read the digital version free here. Other features in the Winter issue include: How to prepare for the… Read More
Late-stage biotech Minoryx is developing a therapy (leriglitazone) targeting patients with the rare progressive CNS disease cerebral adrenoleukodystrophy (cALD). If approved, it would give patients another choice of treatment options outside of stem cell transplants and gene therapies. Data presented last year for leriglitazone showed it stopped cALD disease progression… Read More
What were the trending topics of the year? Here, we run through DDW’s most read articles of 2024. 10: The future outlook for mRNA therapies In this article for the Spring 2024 issue, DDW Editor Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. 9: Key… Read More
In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More
Webinar date: Supported by Amazon Web Services and NVIDIA #News
As 2024 draws to a close, DDW’s Multimedia Editor and podcast host Megan Thomas rounds up all the free editorial episodes of the DDW podcast that were released. You can find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. DDW Highlights Innovative. Evolving. Developing. Busy. These… Read More
To determine where pharma/biopharma regulatory functions see the greatest potential for AI technology, ArisGlobal commissioned an exclusive survey1 of senior regulatory professionals in US pharma and biopharma organisations. The research was conducted in early September 2024. Discussing the findings, Renato Rjavec from ArisGlobal notes that, although plans to invest in regulatory AI… Read More
Across pharma regulatory affairs, quality and pharmacovigilance/drug safety functions, process rigour is wedded tightly to SOPs. But these snapshot definitions of processes do not, of themselves, foster efficiency. In many cases, there has been a loss of sight of the deliverables. Here, Tobias Hitziger, Management Consultant at MAIN5 considers what… Read More
In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More
Webinar date: Supported by Amazon Web Services and NVIDIA #News
#Animal models#Drug development#Drug discovery#The Jackson Laboratory#Vodcast
The latest sponsored DDW Sitting Down With vodcast features Michael Ellis, Senior Director of R&D at The Jackson Laboratory (JAX), and Timothy Robertson, CEO of TLR Ventures and Leader of the Digital In Vivo Alliance to introduce their new digital home cage monitoring system, Envision. Both Ellis and… Read More
The latest sponsored DDW Sitting Down With vodcast features Michael Ellis, Senior Director of R&D at The Jackson Laboratory (JAX), and Timothy Robertson, CEO of TLR Ventures and Leader of the Digital In Vivo Alliance to introduce their new digital home cage monitoring system, Envision. Both Ellis and… Read More